A new Phase 2 pilot study shows that giving spores of a non-toxic C. difficile bacteria by mouth is effective in stopping repeated bouts of C. diff infection, a major complication of hospitalization.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of its final 24-week data from the pivotal Phase 3 ...

NEW YORK (MedscapeWire) Mar 12 — Fulminant colitis with Clostridium difficile is becoming more common and more fatal, according to a review of hospitalized patients reported in the March issue of ...

The portion of our nervous systems responsible for the 'fight or flight' response can shape the severity of potentially deadly C. difficile infections, according to new research. The portion of our ...

Clostridioides difficile risk is significantly higher in Korean patients with inflammatory bowel disease (IBD), which is comparable to the trend observed in Western patients with IBD. There is an ...

New research from the University of Virginia School of Medicine's William A. Petri Jr., MD, PhD, (left) and David Tyus suggests that doctors may be able to save patients from dangerous C. difficile ...

An inflammation of the colon associated with C. difficile — C. difficile colitis — has increased nearly 50 percent from 2001-2005 to 2006-2010, according to a study in the Journal of the American ...

Clostridium difficile infection is four times more likely to kill patients with inflammatory bowel disease. C difficile is an important cause of diarrhea among inpatients, and the numbers of new cases ...

Risk for Clostridioides difficile (C. diff) infection wasn't any greater with vedolizumab (Entyvio) versus anti-tumor necrosis factor (TNF) agents for ulcerative colitis, a researcher reported. In a ...

Research at North Carolina State University shows that the CRISPR-Cas system can be used to effectively target and eliminate specific gut bacteria, in this case Clostridioides difficile, the pathogen ...

PHILADEPHIA — Both initial and sustained responses to fecal microbiota transplant (FMT) for the treatment of refractory C difficile infection remain high out to 18 months' follow-up, provided patients ...

Working in the hospital again always provides valuable perspective. I love (most of) the patient care, and seeing differences in patterns over time, as I only see patients episodically. One of the ...